Care Access Research has announced it is leading a validation trial in conjunction with the FDA for a new at-home COVID-19 test developed by a private genomics lab that manufactures DNA screening kits.

Siemens Healthineers has announced the availability of its molecular Fast Track Diagnostics (FTD) SARS-CoV-2 Assay test kit used to aid in the diagnosis of infection by the SARS-CoV-2 virus that causes COVID-19.

Scientists on Standby is a portal enabling scientists with relevant skills and experience to volunteer their time, expertise and support for COVID-19 screening and testing.

OXGENE™ and The Native Antigen Company have announced a collaboration to scale up their antigen manufacturing capabilities to deliver high-purity, recombinant proteins for the development of diagnostics and vaccines.

PCR Biosystems are continuing to scale up operations to ensure the critical enzyme mix for COVID-19 tests remain available to the UK and global healthcare systems as demand for testing rises.

MicrosensDx has announced that the test for research use in the detection of RNA from the SARS-Cov-2 virus in sputum, throat and nose swabs has now been assessed for clinical performance

Cardea Bio, a San Diego based (bio)technology company, has developed a novel technology combining small bits of biology and semiconductor electronics that can be leveraged to develop a rapid coronavirus handheld test device.

Luminex Corporation has announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its NxTAG® CoV Extended Panel.

FDA grants emergency use authorization for fastest available molecular point-of-care test for novel coronavirus.

The Anti-SARS-CoV-2 ELISAs for immunoglobulin classes A and G from EUROIMMUN, a PerkinElmer, Inc. company, have received the CE mark and can now be applied to COVID-19 diagnostics.